Opella
↗Neuilly-sur-Seine, France
Opella is a global leader in the consumer healthcare market, specializing in over-the-counter (OTC) medicines, vitamins, minerals, and supplements (VMS). Formerly the consumer healthcare division of Sanofi, Opella operates as a standalone company with a portfolio of over 100 iconic brands, including Allegra, Doliprane, Dulcolax, and Mucosolvan, serving more than half a billion consumers worldwide.
Headquartered in France, the company maintains a significant global footprint with 11,000 employees, 13 manufacturing sites, and four specialized science and innovation development centers. Following a 2025 transaction, Opella is now controlled by the private equity firm Clayton, Dubilier & Rice (CD&R), with Sanofi retaining a significant minority stake and Bpifrance holding a small interest.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Consumer Healthcare / OTC
SIZE & FINANCIALS
Employees:10000+
Revenue:$5B-$6B
Founded:2018
Ownership:private
Status:operating
FUNDING
Investors:Clayton, Dubilier & Rice (CD&R), Sanofi, Bpifrance
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Opella North America (Chattem, Inc.), Opella Healthcare France
Key Partnerships:Sanofi (Strategic shareholder and partner), Clayton, Dubilier & Rice (Majority owner)
COMPETITION
Position:Leader
Competitors:Kenvue, Haleon, Bayer Consumer Health, GSK Consumer Healthcare
LEADERSHIP
Key Executives:
Julie Van Ongevalle - CEO
David Taylor - Chairman of the Supervisory Board
LINKS
Website:opella.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Opella and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Opella. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.